Royal Bank Of Canada started coverage on shares of Immune Design Corp. (NASDAQ:IMDZ) in a research note issued to investors on Thursday, The Fly reports. The firm set an “outperform” rating on the biotechnology company’s stock.

A number of other equities analysts also recently weighed in on the stock. ValuEngine raised shares of Immune Design Corp. from a “sell” rating to a “hold” rating in a report on Friday, August 11th. BidaskClub downgraded shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 5th. Zacks Investment Research raised shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a report on Tuesday, July 18th. Jefferies Group LLC reissued a “buy” rating and issued a $18.00 price target on shares of Immune Design Corp. in a report on Wednesday, June 28th. Finally, Cowen and Company reissued a “buy” rating on shares of Immune Design Corp. in a report on Tuesday, June 6th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $14.50.

Immune Design Corp. (NASDAQ IMDZ) traded down 1.59% during mid-day trading on Thursday, hitting $9.30. 107,948 shares of the stock were exchanged. The stock’s 50-day moving average is $9.76 and its 200 day moving average is $7.87. The company’s market capitalization is $238.26 million. Immune Design Corp. has a 52 week low of $4.50 and a 52 week high of $13.05.

Immune Design Corp. (NASDAQ:IMDZ) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.11. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $1.50 million. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. On average, analysts anticipate that Immune Design Corp. will post ($2.39) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/14/royal-bank-of-canada-begins-coverage-on-immune-design-corp-imdz.html.

In other Immune Design Corp. news, Director Lewis W. Coleman acquired 10,000 shares of the company’s stock in a transaction on Monday, July 10th. The shares were acquired at an average cost of $9.00 per share, with a total value of $90,000.00. Following the completion of the acquisition, the director now directly owns 40,000 shares in the company, valued at $360,000. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Lewis W. Coleman acquired 12,000 shares of the company’s stock in a transaction on Tuesday, July 11th. The shares were acquired at an average cost of $9.05 per share, for a total transaction of $108,600.00. Following the completion of the acquisition, the director now owns 40,000 shares of the company’s stock, valued at $362,000. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 30,000 shares of company stock worth $272,760. Insiders own 42.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System lifted its holdings in Immune Design Corp. by 8.3% during the second quarter. California State Teachers Retirement System now owns 30,174 shares of the biotechnology company’s stock valued at $294,000 after purchasing an additional 2,300 shares during the last quarter. Sectoral Asset Management Inc purchased a new stake in Immune Design Corp. during the second quarter valued at about $1,641,000. Goldman Sachs Group Inc. purchased a new stake in Immune Design Corp. during the second quarter valued at about $291,000. Numeric Investors LLC purchased a new stake in Immune Design Corp. during the second quarter valued at about $1,641,000. Finally, Bain Capital Public Equity Management LLC lifted its holdings in Immune Design Corp. by 393.1% during the second quarter. Bain Capital Public Equity Management LLC now owns 389,400 shares of the biotechnology company’s stock valued at $3,797,000 after purchasing an additional 310,433 shares during the last quarter. 51.46% of the stock is currently owned by institutional investors and hedge funds.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

The Fly

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with MarketBeat.com's FREE daily email newsletter.